Medipharm Labs Corp has seen a modest rise in its stock this week, reflecting ongoing developments in the cannabis sector.
Medipharm Labs Corp (LABS.TO) closed at C$0.07 on Friday, marking a 7.14% increase from the previous day. This week, the stock has remained stable, with no significant changes in its performance. Investors are closely watching the company as it navigates various catalysts that could influence its future growth.
Investor takeaway: Investors should consider the recent developments surrounding Medipharm Labs, including its financial performance and strategic moves, while keeping an eye on broader market trends affecting the cannabis sector.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$29.74M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS
Wall Street analysts forecast LABS stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+33.3% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
87.6%
Annualized
90-Day Vol
85.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.06
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.05 – C$0.10 |
| 60 trading days | C$0.07 | C$0.04 – C$0.10 |
| 90 trading days | C$0.06 | C$0.04 – C$0.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$0.07 close with a 7.14% increase in one day.
The stock has fluctuated between C$0.06 and C$0.10 over the past year, indicating a relatively stable trading range but also potential for growth given its current positioning.
Bull case
The company recently announced an 8% annual revenue increase, reaching C$45.1 million, along with significant growth in international medical cannabis revenue. This could signal a positive trajectory, especially with its entry into the European market.
Bear case
Despite the positive revenue growth, Medipharm Labs faces challenges, including a negative profit margin and ongoing volatility in the cannabis sector, which may impact its future performance.
Recent Price Action
Advertisement
This week, Medipharm Labs Corp (LABS.TO) closed at C$0.07, reflecting a 7.14% increase in one day. Over the past month, the stock has maintained steady performance, with a total increase of 7.14%. Year-to-date, the stock has also shown resilience with a 7.14% gain.
Company Developments
Recent headlines indicate that Medipharm Labs has been active in expanding its operations and financial standing. The company reported an 8% increase in annual revenue to C$45.1 million, with a notable 43% growth in international medical cannabis revenue. Additionally, it completed the sale of its Hope, BC facility for $4.5 million to strengthen its financial position. The successful shipment of its first order to France marks a significant milestone in entering the European market, while the U.S. government's decision to reclassify cannabis may unlock further growth opportunities.
Technical Picture
From a technical standpoint, Medipharm Labs is trading at C$0.07, which aligns with both its 50-day and 200-day moving averages (MAs) of C$0.07. The stock has a 52-week range of C$0.06 to C$0.10, indicating it is currently trading at approximately 25% of that range. With a beta of 0.93, the stock has shown slight volatility compared to the market. The latest trading volume was 91,985 shares, which is about 63% of the 20-day average volume of 224,172 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
